Casodex Available for Advanced Prostate Cancer

Oncology NEWS InternationalOncology NEWS International Vol 4 No 11
Volume 4
Issue 11

WILMINGTON, Del--Zeneca Pharmaceutical's Casodex (bicaluta-mide), a new nonsteroidal antiandrogen, has received FDA approval for the hormonal treatment of advanced prostate cancer in combination with a luteinizing-hormone-releasing hormone analog (LHRH-A). The agent acts by binding to cytosol androgen receptors.

WILMINGTON, Del--Zeneca Pharmaceutical's Casodex (bicaluta-mide),a new nonsteroidal antiandrogen, has received FDA approval forthe hormonal treatment of advanced prostate cancer in combinationwith a luteinizing-hormone-releasing hormone analog (LHRH-A).The agent acts by binding to cytosol androgen receptors.

Casodex, available as 50-mg tablets, has the convenience of onetablet, once daily dosing, the company said.

In a large multicenter, double-blind, controlled clinical trial,813 patients with previously untreated advanced prostate cancerwere randomized to receive Casodex, 50 mg once daily, or flutamide(Eulexin), 250 mg three times daily, each in combination withan LHRH-A. At a median follow-up of 95 weeks, time to treatmentfailure with use of Casodex/LHRH-A therapy was similar to thatof flutamide/LHRH-A therapy.

At the same timepoint, 130 patients (32%) treated with the Casodexcombination and 145 (35%) treated with the flutamide combinationhad died. Assessment of quality of life questionnaires indicatedno significant differences between the two treatment groups.

In this study, the most frequent adverse experience with Casodexwas hot flashes (49%). Diarrhea was the adverse event most frequentlyleading to treatment withdrawal: 6% of patients treated with flutamide/LHRH-Aand 0.5% of patients treated with Casodex/LHRH-A. Of those onCasodex, 10% reported diarrhea, compared with 24% on flutamide.

Other adverse effects of Casodex included pain (general) (27%),back pain (15%), asthenia (15%), pelvic pain (13%), infection(10%), constipation (17%), and nausea (11%).

"I believe it's important to give prostate cancer patientsa choice of treatments," said Gerald W. Chodak, MD, codirector,Urologic Oncology, University of Chicago Hospitals and Clinics,and an investigator in the Casodex clinical trials. "Theavailability of Casodex means that patients choosing combinationdrug therapy can lower the chances that they will have diarrheaas a side effect of the antiandrogen," he said.

Related Videos
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Related Content